Betahistine for symptoms of vertigo
Vertigo is a symptom in which individuals experience a false sensation of movement. This type of dizziness is thought to originate in the inner ear labyrinth or its neural connections. It is a commonly experienced symptom and can cause significant problems with carrying out normal activities. Betahi...
Uloženo v:
| Vydáno v: | Cochrane database of systematic reviews číslo 6; s. CD010696 |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
England
21.06.2016
|
| Témata: | |
| ISSN: | 1469-493X, 1469-493X |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Vertigo is a symptom in which individuals experience a false sensation of movement. This type of dizziness is thought to originate in the inner ear labyrinth or its neural connections. It is a commonly experienced symptom and can cause significant problems with carrying out normal activities. Betahistine is a drug that may work by improving blood flow to the inner ear. This review examines whether betahistine is more effective than a placebo at treating symptoms of vertigo from different causes.
To assess the effects of betahistine in patients with symptoms of vertigo from different causes.
The Cochrane ENT Information Specialist searched the Cochrane ENT Trials Register; Central Register of Controlled Trials (CENTRAL 2015, Issue 8); PubMed; EMBASE; CINAHL; Web of Science; ClinicalTrials.gov; ICTRP and additional sources for published and unpublished trials. We also contacted manufacturers and researchers in the field. The date of the search was 21 September 2015.
We included randomised controlled trials of betahistine versus placebo in patients of any age with vertigo from any neurotological diagnosis in any settings.
We used the standard methodological procedures expected by Cochrane. Our primary outcome was the proportion of patients with reduction in vertigo symptoms (considering together the intensity, frequency and duration those symptoms).
We included 17 studies, with a total of 1025 participants; 12 studies were published (567 patients) and five were unpublished (458 patients). Sixteen studies including 953 people compared betahistine with placebo. All studies with analysable data lasted three months or less. The majority were at high risk of bias, but in some the risk of bias was unclear. One study, at high risk of bias, included 72 people with benign paroxysmal positional vertigo (BPPV) and compared betahistine with placebo; all patients also had particle repositioning manoeuvres. The studies varied considerably in terms of types of participants, their diagnoses, the dose of betahistine and the length of time it was taken for, the study methods and the way any improvement in vertigo symptoms was measured. Using the GRADE system, we judged the quality of evidence overall to be low for two outcomes (proportion of patients with improvement and proportion with adverse events).Pooled data showed that the proportion of patients reporting an overall reduction in their vertigo symptoms was higher in the group treated with betahistine than the placebo group: risk ratio (RR) 1.30, 95% confidence interval (CI) 1.05 to 1.60; 606 participants; 11 studies). This result should be interpreted with caution as the test for statistical heterogeneity as measured by the I(2) value was high.Adverse effects (mostly gastrointestinal symptoms and headache) were common but medically serious events in the study were rare and isolated: there was no difference in the frequency of adverse effects between the betahistine and placebo groups, where the rates were 16% and 15% respectively (weighted values, RR 1.03, 95% CI 0.76 to 1.40; 819 participants; 12 studies).Sixteen per cent of patients from both the betahistine and the placebo groups withdrew (dropped out) from the studies (RR 0.96, 95% CI 0.65 to 1.42; 481 participants; eight studies).Three studies looked at objective vestibular function tests as an outcome; the numbers of participants were small, techniques of measurement very diverse and reporting details sparse, so analysis of this outcome was inconclusive.We looked for information on generic quality of life and falls, but none of the studies reported on these outcomes.
Low quality evidence suggests that in patients suffering from vertigo from different causes there may be a positive effect of betahistine in terms of reduction in vertigo symptoms. Betahistine is generally well tolerated with a low risk of adverse events. Future research into the management of vertigo symptoms needs to use more rigorous methodology and include outcomes that matter to patients and their families. |
|---|---|
| AbstractList | Vertigo is a symptom in which individuals experience a false sensation of movement. This type of dizziness is thought to originate in the inner ear labyrinth or its neural connections. It is a commonly experienced symptom and can cause significant problems with carrying out normal activities. Betahistine is a drug that may work by improving blood flow to the inner ear. This review examines whether betahistine is more effective than a placebo at treating symptoms of vertigo from different causes.BACKGROUNDVertigo is a symptom in which individuals experience a false sensation of movement. This type of dizziness is thought to originate in the inner ear labyrinth or its neural connections. It is a commonly experienced symptom and can cause significant problems with carrying out normal activities. Betahistine is a drug that may work by improving blood flow to the inner ear. This review examines whether betahistine is more effective than a placebo at treating symptoms of vertigo from different causes.To assess the effects of betahistine in patients with symptoms of vertigo from different causes.OBJECTIVESTo assess the effects of betahistine in patients with symptoms of vertigo from different causes.The Cochrane ENT Information Specialist searched the Cochrane ENT Trials Register; Central Register of Controlled Trials (CENTRAL 2015, Issue 8); PubMed; EMBASE; CINAHL; Web of Science; ClinicalTrials.gov; ICTRP and additional sources for published and unpublished trials. We also contacted manufacturers and researchers in the field. The date of the search was 21 September 2015.SEARCH METHODSThe Cochrane ENT Information Specialist searched the Cochrane ENT Trials Register; Central Register of Controlled Trials (CENTRAL 2015, Issue 8); PubMed; EMBASE; CINAHL; Web of Science; ClinicalTrials.gov; ICTRP and additional sources for published and unpublished trials. We also contacted manufacturers and researchers in the field. The date of the search was 21 September 2015.We included randomised controlled trials of betahistine versus placebo in patients of any age with vertigo from any neurotological diagnosis in any settings.SELECTION CRITERIAWe included randomised controlled trials of betahistine versus placebo in patients of any age with vertigo from any neurotological diagnosis in any settings.We used the standard methodological procedures expected by Cochrane. Our primary outcome was the proportion of patients with reduction in vertigo symptoms (considering together the intensity, frequency and duration those symptoms).DATA COLLECTION AND ANALYSISWe used the standard methodological procedures expected by Cochrane. Our primary outcome was the proportion of patients with reduction in vertigo symptoms (considering together the intensity, frequency and duration those symptoms).We included 17 studies, with a total of 1025 participants; 12 studies were published (567 patients) and five were unpublished (458 patients). Sixteen studies including 953 people compared betahistine with placebo. All studies with analysable data lasted three months or less. The majority were at high risk of bias, but in some the risk of bias was unclear. One study, at high risk of bias, included 72 people with benign paroxysmal positional vertigo (BPPV) and compared betahistine with placebo; all patients also had particle repositioning manoeuvres. The studies varied considerably in terms of types of participants, their diagnoses, the dose of betahistine and the length of time it was taken for, the study methods and the way any improvement in vertigo symptoms was measured. Using the GRADE system, we judged the quality of evidence overall to be low for two outcomes (proportion of patients with improvement and proportion with adverse events).Pooled data showed that the proportion of patients reporting an overall reduction in their vertigo symptoms was higher in the group treated with betahistine than the placebo group: risk ratio (RR) 1.30, 95% confidence interval (CI) 1.05 to 1.60; 606 participants; 11 studies). This result should be interpreted with caution as the test for statistical heterogeneity as measured by the I(2) value was high.Adverse effects (mostly gastrointestinal symptoms and headache) were common but medically serious events in the study were rare and isolated: there was no difference in the frequency of adverse effects between the betahistine and placebo groups, where the rates were 16% and 15% respectively (weighted values, RR 1.03, 95% CI 0.76 to 1.40; 819 participants; 12 studies).Sixteen per cent of patients from both the betahistine and the placebo groups withdrew (dropped out) from the studies (RR 0.96, 95% CI 0.65 to 1.42; 481 participants; eight studies).Three studies looked at objective vestibular function tests as an outcome; the numbers of participants were small, techniques of measurement very diverse and reporting details sparse, so analysis of this outcome was inconclusive.We looked for information on generic quality of life and falls, but none of the studies reported on these outcomes.MAIN RESULTSWe included 17 studies, with a total of 1025 participants; 12 studies were published (567 patients) and five were unpublished (458 patients). Sixteen studies including 953 people compared betahistine with placebo. All studies with analysable data lasted three months or less. The majority were at high risk of bias, but in some the risk of bias was unclear. One study, at high risk of bias, included 72 people with benign paroxysmal positional vertigo (BPPV) and compared betahistine with placebo; all patients also had particle repositioning manoeuvres. The studies varied considerably in terms of types of participants, their diagnoses, the dose of betahistine and the length of time it was taken for, the study methods and the way any improvement in vertigo symptoms was measured. Using the GRADE system, we judged the quality of evidence overall to be low for two outcomes (proportion of patients with improvement and proportion with adverse events).Pooled data showed that the proportion of patients reporting an overall reduction in their vertigo symptoms was higher in the group treated with betahistine than the placebo group: risk ratio (RR) 1.30, 95% confidence interval (CI) 1.05 to 1.60; 606 participants; 11 studies). This result should be interpreted with caution as the test for statistical heterogeneity as measured by the I(2) value was high.Adverse effects (mostly gastrointestinal symptoms and headache) were common but medically serious events in the study were rare and isolated: there was no difference in the frequency of adverse effects between the betahistine and placebo groups, where the rates were 16% and 15% respectively (weighted values, RR 1.03, 95% CI 0.76 to 1.40; 819 participants; 12 studies).Sixteen per cent of patients from both the betahistine and the placebo groups withdrew (dropped out) from the studies (RR 0.96, 95% CI 0.65 to 1.42; 481 participants; eight studies).Three studies looked at objective vestibular function tests as an outcome; the numbers of participants were small, techniques of measurement very diverse and reporting details sparse, so analysis of this outcome was inconclusive.We looked for information on generic quality of life and falls, but none of the studies reported on these outcomes.Low quality evidence suggests that in patients suffering from vertigo from different causes there may be a positive effect of betahistine in terms of reduction in vertigo symptoms. Betahistine is generally well tolerated with a low risk of adverse events. Future research into the management of vertigo symptoms needs to use more rigorous methodology and include outcomes that matter to patients and their families.AUTHORS' CONCLUSIONSLow quality evidence suggests that in patients suffering from vertigo from different causes there may be a positive effect of betahistine in terms of reduction in vertigo symptoms. Betahistine is generally well tolerated with a low risk of adverse events. Future research into the management of vertigo symptoms needs to use more rigorous methodology and include outcomes that matter to patients and their families. Vertigo is a symptom in which individuals experience a false sensation of movement. This type of dizziness is thought to originate in the inner ear labyrinth or its neural connections. It is a commonly experienced symptom and can cause significant problems with carrying out normal activities. Betahistine is a drug that may work by improving blood flow to the inner ear. This review examines whether betahistine is more effective than a placebo at treating symptoms of vertigo from different causes. To assess the effects of betahistine in patients with symptoms of vertigo from different causes. The Cochrane ENT Information Specialist searched the Cochrane ENT Trials Register; Central Register of Controlled Trials (CENTRAL 2015, Issue 8); PubMed; EMBASE; CINAHL; Web of Science; ClinicalTrials.gov; ICTRP and additional sources for published and unpublished trials. We also contacted manufacturers and researchers in the field. The date of the search was 21 September 2015. We included randomised controlled trials of betahistine versus placebo in patients of any age with vertigo from any neurotological diagnosis in any settings. We used the standard methodological procedures expected by Cochrane. Our primary outcome was the proportion of patients with reduction in vertigo symptoms (considering together the intensity, frequency and duration those symptoms). We included 17 studies, with a total of 1025 participants; 12 studies were published (567 patients) and five were unpublished (458 patients). Sixteen studies including 953 people compared betahistine with placebo. All studies with analysable data lasted three months or less. The majority were at high risk of bias, but in some the risk of bias was unclear. One study, at high risk of bias, included 72 people with benign paroxysmal positional vertigo (BPPV) and compared betahistine with placebo; all patients also had particle repositioning manoeuvres. The studies varied considerably in terms of types of participants, their diagnoses, the dose of betahistine and the length of time it was taken for, the study methods and the way any improvement in vertigo symptoms was measured. Using the GRADE system, we judged the quality of evidence overall to be low for two outcomes (proportion of patients with improvement and proportion with adverse events).Pooled data showed that the proportion of patients reporting an overall reduction in their vertigo symptoms was higher in the group treated with betahistine than the placebo group: risk ratio (RR) 1.30, 95% confidence interval (CI) 1.05 to 1.60; 606 participants; 11 studies). This result should be interpreted with caution as the test for statistical heterogeneity as measured by the I(2) value was high.Adverse effects (mostly gastrointestinal symptoms and headache) were common but medically serious events in the study were rare and isolated: there was no difference in the frequency of adverse effects between the betahistine and placebo groups, where the rates were 16% and 15% respectively (weighted values, RR 1.03, 95% CI 0.76 to 1.40; 819 participants; 12 studies).Sixteen per cent of patients from both the betahistine and the placebo groups withdrew (dropped out) from the studies (RR 0.96, 95% CI 0.65 to 1.42; 481 participants; eight studies).Three studies looked at objective vestibular function tests as an outcome; the numbers of participants were small, techniques of measurement very diverse and reporting details sparse, so analysis of this outcome was inconclusive.We looked for information on generic quality of life and falls, but none of the studies reported on these outcomes. Low quality evidence suggests that in patients suffering from vertigo from different causes there may be a positive effect of betahistine in terms of reduction in vertigo symptoms. Betahistine is generally well tolerated with a low risk of adverse events. Future research into the management of vertigo symptoms needs to use more rigorous methodology and include outcomes that matter to patients and their families. |
| Author | Schilder, Anne G M Murdin, Louisa Hussain, Kiran |
| Author_xml | – sequence: 1 givenname: Louisa surname: Murdin fullname: Murdin, Louisa organization: Ear Institute, Faculty of Brain Sciences, University College London, London, UK – sequence: 2 givenname: Kiran surname: Hussain fullname: Hussain, Kiran – sequence: 3 givenname: Anne G M surname: Schilder fullname: Schilder, Anne G M |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27327415$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNj0tLw0AUhQep2If-hRJw4ybx3nkkM0tNfUHBjYK7MJPeaKTJxEwi9N8bsIKr78D5OHCWbNb6lhhbIyQIwK9Rpgq10km-AYTUpEk3On7CFlNhYmnE2-xfnrNlCJ8AwiDqMzbnmeCZRLVgl7c02I86DHVLUeX7KByabvBNiHwVfVM_1O_-nJ1Wdh_o4sgVe72_e8kf4-3zw1N-s41LaQyPM1uVGp0jdDZzRk1UQCQASShdplIILDWAMrusmmgrRbrUO0rBATrOV-zqd7fr_ddIYSiaOpS039uW_BgK1ICSS5XKSV0f1dE1tCu6vm5sfyj-jvEfq3JSHg |
| CitedBy_id | crossref_primary_10_1007_s40266_021_00877_z crossref_primary_10_1038_s41467_021_27138_2 crossref_primary_10_1159_000515821 crossref_primary_10_2147_DDDT_S329547 crossref_primary_10_3389_fneur_2023_1175481 crossref_primary_10_3389_fvets_2023_1263976 crossref_primary_10_1080_19932820_2020_1808361 crossref_primary_10_3390_diagnostics11020329 crossref_primary_10_1093_rpsppr_rqaf003 crossref_primary_10_1007_s00228_020_02833_z crossref_primary_10_1007_s00228_020_02834_y crossref_primary_10_1007_s00228_018_02617_6 crossref_primary_10_5812_jrps_158540 crossref_primary_10_7759_cureus_87843 crossref_primary_10_1007_s11696_023_02873_6 crossref_primary_10_1177_19160216241265685 crossref_primary_10_3389_fneur_2016_00136 crossref_primary_10_1007_s00415_018_8809_8 crossref_primary_10_1007_s00415_024_12423_z crossref_primary_10_3389_fneur_2017_00124 crossref_primary_10_1007_s44266_023_00065_9 crossref_primary_10_1186_s12920_019_0533_4 crossref_primary_10_1007_s00234_024_03535_4 crossref_primary_10_1212_CON_0000000000000958 crossref_primary_10_3389_fneur_2021_642137 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1002/14651858.CD010696.pub2 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1469-493X |
| ExternalDocumentID | 27327415 |
| Genre | Meta-Analysis Research Support, Non-U.S. Gov't Systematic Review Journal Article |
| GrantInformation_xml | – fundername: Department of Health grantid: NIHR-RP-011-045 |
| GroupedDBID | --- 53G 5GY 7PX 9HA ABJNI ACGFO ACGFS AENEX ALMA_UNASSIGNED_HOLDINGS ALUQN AYR CGR CUY CVF D7G ECM EIF HYE NPM OEC OK1 P2P RWY WOW ZYTZH 7X8 |
| ID | FETCH-LOGICAL-c4992-7afc81bbe1ba7b95e1b50ee301e358c64331c80059d7f800af5e8c8de60b01b22 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 74 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000381106800034&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1469-493X |
| IngestDate | Thu Jul 10 17:08:29 EDT 2025 Sat Jun 28 01:34:49 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4992-7afc81bbe1ba7b95e1b50ee301e358c64331c80059d7f800af5e8c8de60b01b22 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 ObjectType-Undefined-4 |
| OpenAccessLink | https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010696.pub2/pdf/full |
| PMID | 27327415 |
| PQID | 1801424564 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1801424564 pubmed_primary_27327415 |
| PublicationCentury | 2000 |
| PublicationDate | 2016-06-21 |
| PublicationDateYYYYMMDD | 2016-06-21 |
| PublicationDate_xml | – month: 06 year: 2016 text: 2016-06-21 day: 21 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Cochrane database of systematic reviews |
| PublicationTitleAlternate | Cochrane Database Syst Rev |
| PublicationYear | 2016 |
| SSID | ssj0039118 |
| Score | 2.4656534 |
| SecondaryResourceType | review_article |
| Snippet | Vertigo is a symptom in which individuals experience a false sensation of movement. This type of dizziness is thought to originate in the inner ear labyrinth... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | CD010696 |
| SubjectTerms | Benign Paroxysmal Positional Vertigo - drug therapy Betahistine - adverse effects Betahistine - therapeutic use Humans Randomized Controlled Trials as Topic Vertigo - drug therapy |
| Title | Betahistine for symptoms of vertigo |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/27327415 https://www.proquest.com/docview/1801424564 |
| WOSCitedRecordID | wos000381106800034&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8QwEB7UFfHi-7G-qOi17jZtmvQkurp42WUPCr2VJE3Ew7arXQX_vTNtV0-C4KWh0EKTzKTfPD-AyyQ3gUK7wHf4gB_FTPk6ybkfCBk4zhTaua4mmxDjsUzTZNI63Ko2rXJxJtYHdV4a8pH3AmpzQlG66Hr26hNrFEVXWwqNZeiECGVIqkX6HUUIUZFlU11ETGphuqgQ7rNeQBzgksurwR1ZRUlM02e_w8z6dzPc_O-HbsFGCzS9m0YytmHJFjuwNmpD6btwcWvniroN452HyNWrPqezeTmtvNJ5NUnzc7kHT8P7x8GD3zIm-CaiNFKhnEEcqm2gldAJx5H3rUUltiGXJqbyKCOp4DQXDkfluJVG5jYmf6hmbB9WirKwh-AZTdBJ5Uo5Edko1iYUiYxMzmUYSe26cL6YfoYSSWEGVdjyvcp-FqALB80aZrOmdUaGYIn65fCjP7x9DOuITmLKy2LBCXQc6qM9hVXzMX-p3s7qrcbreDL6AlFnsaI |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Betahistine+for+symptoms+of+vertigo&rft.jtitle=Cochrane+database+of+systematic+reviews&rft.au=Murdin%2C+Louisa&rft.au=Hussain%2C+Kiran&rft.au=Schilder%2C+Anne+G+M&rft.date=2016-06-21&rft.eissn=1469-493X&rft.issue=6&rft.spage=CD010696&rft_id=info:doi/10.1002%2F14651858.CD010696.pub2&rft_id=info%3Apmid%2F27327415&rft_id=info%3Apmid%2F27327415&rft.externalDocID=27327415 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1469-493X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1469-493X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1469-493X&client=summon |